HLA-DR antigens in gold-induced neutropenia.
We studied the clinical courses of 9 patients who developed acute gold-induced neutropenia with marrow aplasia. Eight of these carried HLA-DR4, compared with only 2 of 9 who had mild, chronic, isolated neutropenia (P less than 0.05). Only 1 of 9 patients with myelotoxicity carried HLA-DR3. We conclude that these groups are immunogenetically distinct, and that HLA-DR3 is not a significant risk factor for severe gold-induced neutropenia.
D000208:Acute Disease; D000380:Agranulocytosis / Q000276:immunology*; D001168:Arthritis / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002908:Chronic Disease; D006052:Gold Sodium Thiomalate / Q000009:adverse effects* / Q000627:therapeutic use; D006680:HLA Antigens / Q000235:genetics; D006681:HLA-D Antigens / Q000032:analysis*; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000235:genetics / Q000276:immunology*; D010641:Phenotype; D011565:Psoriasis / Q000188:drug therapy
D006680:HLA Antigens; D006681:HLA-D Antigens; D006684:HLA-DR Antigens; D006052:Gold Sodium Thiomalate